Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Solid and Hematological Cancers. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer […]

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Hematological and Solid Tumors. Bone E.A., Cecil A.R.L., Colman L., Finan P., Finnemore D., Gatland A., Haque K., Lensun L., Rogers H., Silva F.A., Whale A., Shuttleworth S.J. Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; […]

Karus Therapeutics presenting at Sachs Immuno-oncology: BD&L and Investment Forum

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of cancer and inflammatory disease, has announced that it will be presenting at Sachs Immuno-oncology: BD&L and Investment Forum, Chicago, USA, 29th May 2015. Stephen Shuttleworth, Karus’s CSO, will present and CEO Simon Kerry will also be attending the conference. For more […]